Eli Lilly - 10 Largest U.S. Patent Losses

Drug: Zyprexa
Company: Eli Lilly
2010 U.S. sales: $2.495 billion/$5.026 billion global
Impact: 19.4% of U.S. sales
Exclusivity expires: October 2011

Due to safety questions and highly publicized litigation--not to mention a $1.42 billion off-label marketing settlement--Zyprexa sales have flattened out over the last two years. The drug remains Lilly's biggest worldwide seller, and that fact has analysts and investors worried. Lilly admits the post-Zyprexa era will be tough. It even has a code name for that period: Years YZ.

CEO John Lechleiter (photo) faces the question regularly: What's going to take Zyprexa's place? He has fought off the notion Lilly needs to make a convenient marriage once Zyprexa goes off patent. The words "no megamergers" have passed his lips so often, they're almost a mantra. He has reminded the world that Lilly dealt with losing protection on a major CNS drug before: Prozac. Still, with Cymbalta's patent expiration looming, the company will soon have another multibillion-dollar gap to fill.

Eli Lilly - 10 Largest U.S. Patent Losses

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.